ENTA News and Press, Enanta Pharmaceuticals Inc. From 01/09/20

Presentation and Q&A breakout to be webcast on January 13, 2020 beginning at 2:30 p.m. Pacific Time Several clinical milestones expected in RSV, HBV, and NASH/PBC programs in 2020 New discovery program in human metapneumovirus (hMPV) Strong balance sheet and royalty ...

Presentation and Question and Answer Session to be Webcast beginning at 2:30 p.m. PT on January 13, 2020 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today anno...

Enanta Pharmaceuticals (NASDAQ: ENTA ) cut by JMP Securities analyst Liisa Bayko to market perform from market outperform after the company turned in weaker-than-expected fiscal Q4 results. More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, ...

Enanta Pharmaceuticals ' (NASDAQ: ENTA) got off to a great start in 2019 with its shares soaring more than 40%. It's been downhill since the first quarter, though. The pharma stock is now down more than 10% year to date. Any hopes that Enanta's fiscal 2019 fourth-quarter results would help t...

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2019 Earnings Conference Call November 21, 2019, 04:30 PM ET Company Participants Carol Miceli - Director, IR Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - SVP and Chief Medical Officer Conference Call Participants ...

Image source: The Motley Fool. Enanta Pharmaceuticals Inc   (NASDAQ: ENTA) Q4 2019 Earnings Call Nov 21, 2019 , 4:30 p.m. ET Operator Continue reading

Enanta Pharma (NASDAQ: ENTA ): Q4 GAAP EPS of $0.44 misses by $0.12 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Webcast and Conference Call today at 4:30 p.m. ET Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV EDP-297 selected as follow-on FXR agonist with differentiated preclinical profile Royalty revenue for the quarter was $51.3 million Cash a...

ENTA , GPS , INTU , JWN , MATW , POST , PSTG , ROST , SCVL , SPLK , WSM For Seeking Alpha's full earnings season calendar,  click here . More news on: Enanta Pharmaceuticals, Inc., The Gap, Inc., Intuit Inc., Earnings news and commentary,

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305, Enanta’s lead Farnesoid X receptor (FXR) agonist, will be presente...